neopharm.com Revenue and Competitors
Estimated Revenue & Valuation
- neopharm.com's estimated annual revenue is currently $11.3M per year.
- neopharm.com's estimated revenue per employee is $201,000
Employee Data
- neopharm.com has 56 Employees.
- neopharm.com grew their employee count by -12% last year.
neopharm.com's People
| Name | Title | Email/Phone |
|---|
neopharm.com Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $46.2M | 230 | 5% | N/A | N/A |
#2 | $43.8M | 218 | 21% | N/A | N/A |
#3 | $57.1M | 284 | 26% | N/A | N/A |
#4 | $24.5M | 122 | 3% | N/A | N/A |
#5 | $52.9M | 263 | 13% | N/A | N/A |
#6 | $24.7M | 123 | 13% | N/A | N/A |
#7 | $1.8M | 18 | 0% | $114.3M | N/A |
#8 | $7.2M | 36 | -20% | N/A | N/A |
#9 | $13.7M | 68 | -7% | N/A | N/A |
#10 | $7.6M | 39 | -13% | $123.9M | N/A |
What Is neopharm.com?
NeoPharm is a publicly traded biopharmaceutical company engaged in the research, development, and commercialization of drugs for the treatment of various cancers and other diseases. NeoPharm has built its drug development program around two proprietary technology platforms: a tumor-targeting toxin platform which includes development for a new indication of Pulmonary Fibrosis, and a novel NeoLipid® liposomal drug delivery system. The company has advanced five drug product candidates in various stages of clinical and pre-clinical development for the treatment of cancer and one drug product candidate in pre-clinical development for treatment of interstitial pulmonary fibrosis, or IPF, and asthma. NeoPharm's stock is traded over-the-counter (OTC) under the stock symbol NEOL.PK. NeoPharm's corporate office and research and development facility is located in Lake Bluff, Illinois. NeoPharm's new management team, enlisted in March of 2007, has undertaken a concentrated plan.
keywords:N/A
N/A
Total Funding
56
Number of Employees
$11.3M
Revenue (est)
-12%
Employee Growth %
N/A
Valuation
N/A
Accelerator
neopharm.com News
... presented at the event: G-Medical, RenalSense, IGIN Smart, Appscent, Synergy 3d-Med, ALTA Medical, NeoPharm Israel, and Tuttenauer.
Larry's career progressed into leadership roles serving as CEO of Aksys, (Home Hemodialysis) and NeoPharm (Oncology Biotech).
... Ierative Scopes, Rafa Laboratories, Neopharm, Nestle, Arena Pharmaceuticals, Gilead Sciences, Galapagos, MSD, Celltrion, Sublimity Therapeutics, Sandoz,...
Other Companies in
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $12.8M | 56 | 6% | N/A |
#2 | $9.1M | 56 | 0% | N/A |
#3 | $35M | 56 | 6% | N/A |
#4 | $16.2M | 56 | 12% | N/A |
#5 | $16.6M | 56 | -12% | N/A |